Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK Cells and Epratuzumab for Relapsed ALL
NCT00941928Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2009
- Primary completion
- May 2012
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of epratuzumab and haploidentical natural killer cells in acute lymphoblastic leukemia (ALL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Time to Progression at 1 year, Feasibility of collecting NK cells and 1 more. Started Jul 2009; status: terminated.
02
Drugs
epratuzumabhaploidentical natural killer cells
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00941928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00941928.